Related Experiment Videos
Clinical development of Taxol
S G Arbuck1, M C Christian, J S Fisherman
1M. A. Friedman, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892.
Journal of the National Cancer Institute. Monographs
|January 1, 1993
Summary
Paclitaxel, a novel anticancer drug, effectively treats ovarian, breast, lung, and head/neck cancers by stabilizing microtubules. Further research is ongoing to optimize its use and combination therapies for broader applications.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Paclitaxel (Taxol) represents a new class of anticancer agents, the taxanes.
- Its unique mechanism involves polymerizing tubulin into stable microtubules and bundles.
- Development involved overcoming formulation, supply, hypersensitivity, and efficacy challenges.
Purpose of the Study:
- To review the clinical development of Paclitaxel.
- To present the current status of Phase I, II, and III clinical trials.
- To highlight demonstrated clinical efficacy and ongoing research for optimal use.
Main Methods:
- Review of clinical trial data (Phase I, II, and III).
- Analysis of Paclitaxel's mechanism of action on tubulin polymerization.
- Assessment of efficacy and safety across various cancer types.
Main Results:
- Demonstrated clinical efficacy in ovarian, breast, non-small-cell lung, and head and neck cancers.
- Received FDA approval in December 1992 for second-line ovarian cancer therapy.
- Ongoing evaluation for melanoma, prostate, colon, cervix, and renal cancers with dose/schedule adjustments.
Conclusions:
- Paclitaxel is an important new anticancer drug with demonstrated efficacy in several malignancies.
- Optimal dosing, scheduling, and combination chemotherapy regimens require further investigation.
- Continued clinical trials are essential for maximizing Paclitaxel's therapeutic potential.